382 related articles for article (PubMed ID: 17545791)
21. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
Wingard JR; Elmongy M
Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
[TBL] [Abstract][Full Text] [Related]
22. Neutropenia: state of the knowledge part I.
Nirenberg A; Bush AP; Davis A; Friese CR; Gillespie TW; Rice RD
Oncol Nurs Forum; 2006 Nov; 33(6):1193-201. PubMed ID: 17149402
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
Crawford J; Dale DC; Lyman GH
Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
[TBL] [Abstract][Full Text] [Related]
25. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
Crawford J
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
[TBL] [Abstract][Full Text] [Related]
26. [Evidence-based management of neutropenia and fever].
Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
[TBL] [Abstract][Full Text] [Related]
27. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
28. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
29. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
30. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
J Natl Compr Canc Netw; 2007 Feb; 5(2):217-28. PubMed ID: 17335690
[TBL] [Abstract][Full Text] [Related]
31. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
32. Are guidelines on use of colony-stimulating factors in solid cancers flawed?
Haines IE; Olver I
Intern Med J; 2009 Apr; 39(4):259-62. PubMed ID: 19402867
[TBL] [Abstract][Full Text] [Related]
33. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
Shochat E; Rom-Kedar V
Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
[TBL] [Abstract][Full Text] [Related]
34. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
35. Advances in the use of colony-stimulating factors for chemotherapy-induced neutropenia.
Dale DC
J Support Oncol; 2005; 3(2 Suppl 1):39-41. PubMed ID: 15794500
[No Abstract] [Full Text] [Related]
36. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
37. [Colony stimulating factors in chemotherapy induced neutropenic fever].
Sanz Rubiales A; García Alvarez G; Centeno Cortés C; Martín Ortega Y; Del Valle Rivero AL; Nieto Sanz J
An Med Interna; 1998 Feb; 15(2):100-4. PubMed ID: 9542208
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment in oncology clinical practice. From risk factors to risk models.
Lyman GH
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
[TBL] [Abstract][Full Text] [Related]
39. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
Khan S; Dhadda A; Fyfe D; Sundar S
Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
[TBL] [Abstract][Full Text] [Related]
40. NCCN guidelines advocate wider use of colony-stimulating factor.
McNeil C
J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
